Zogenix announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of
hydrocodone without acetaminophenSAN DIEGO, CA, USA | March 17, 2010 | Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical ...
[Published Mar 19 2010 by PipelineReview]